{"schema_version":"1.0","type":"article","title":"Weight-loss shots stop short of cirrhosis, so Novo bought a $4.7B fix","url":"https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en.md","lang":"en","date":"2026-11-13","publish_at":"2026-11-13T08:00:00+08:00","updated_at":"2026-11-13","category":"醫學大會","topic":"醫學大會","tags":["MASH","cirrhosis","FGF21","Novo Nordisk","AASLD 2026"],"summary":"AASLD 2026 data show GLP-1s resolve MASH far more than they reverse fibrosis. Novo's Akero CVR and Roche's 89bio CVR both hinge on cirrhosis, while Rezdiffra grew 50% with up to 53% GLP-1 co-use.","key_points":["At AASLD 2026, survodutide patients losing 15% or more saw 78.4% MASH resolution but 64.9% fibrosis improvement.","Novo's Akero CVR and Roche's 89bio CVR both depend on FGF21 success in cirrhosis.","Rezdiffra Q3 2026 sales reached $431.3 million, up 50%, with up to 53% of patients also on a GLP-1."],"facts":[{"claim":"ESSENCE week-72 MASH resolution, semaglutide vs placebo","value":"63 vs 34","unit":"%","as_of":"2025-08-15","source":"HCPLive 2025-08-15"},{"claim":"ESSENCE week-72 fibrosis improvement, semaglutide vs placebo","value":"37 vs 22","unit":"%","as_of":"2025-08-15","source":"HCPLive 2025-08-15"},{"claim":"Survodutide MASH resolution, weight loss ≥15%","value":"78.4","unit":"%","as_of":"2026-11-07","source":"HCPLive 2026-11-07"},{"claim":"Survodutide fibrosis improvement, weight loss ≥15%","value":"64.9","unit":"%","as_of":"2026-11-07","source":"HCPLive 2026-11-07"},{"claim":"Survodutide MASH resolution / fibrosis improvement, weight loss <5%","value":"36.8 / 47.4","unit":"%","as_of":"2026-11-07","source":"HCPLive 2026-11-07"},{"claim":"Saroglitazar 4 mg MASH resolution vs placebo","value":"39.1 vs 13.7","unit":"%","as_of":"2026-11-08","source":"Tech Times 2026-11-08"},{"claim":"Saroglitazar 4 mg fibrosis improvement vs placebo (not significant)","value":"34.8 vs 24.6","unit":"%","as_of":"2026-11-08","source":"Tech Times 2026-11-08"},{"claim":"Semaglutide phase 2 in compensated cirrhosis, fibrosis improvement vs placebo","value":"11 vs 29","unit":"%","as_of":"2023-03-20","source":"HCPLive 2023-03-20"},{"claim":"Novo cash consideration for Akero","value":"47","unit":"x100M USD","as_of":"2025-10-09","source":"Novo Nordisk 2025-10-09"},{"claim":"Akero CVR tied to US cirrhosis approval","value":"6 / ~5","unit":"USD per share / x100M USD","as_of":"2025-10-09","source":"Novo Nordisk 2025-10-09"},{"claim":"Efruxifermin SYMMETRY 96-week fibrosis improvement in cirrhosis vs placebo","value":"29 vs 11","unit":"%","as_of":"2025-10-09","source":"Novo Nordisk 2025-10-09"},{"claim":"Roche 89bio deal maximum value","value":"35","unit":"x100M USD","as_of":"2025-09-18","source":"Fierce Biotech 2025-09-18"},{"claim":"Rezdiffra Q3 2026 net sales","value":"4.313","unit":"x100M USD","as_of":"2026-11-03","source":"SEC 2026-11-03"},{"claim":"Rezdiffra sales growth YoY","value":"50","unit":"%","as_of":"2026-11-03","source":"SEC 2026-11-03"},{"claim":"Rezdiffra patients on therapy","value":"55850","unit":"people","as_of":"2026-09-30","source":"SEC 2026-11-03"},{"claim":"Rezdiffra patients also on GLP-1 (up to)","value":"53","unit":"%","as_of":"2026-11-05","source":"Madrigal 2026-11-05"},{"claim":"Liver-related death risk after progression to cirrhosis","value":"42","unit":"fold","as_of":"2026-11-05","source":"Madrigal 2026-11-05"},{"claim":"Taiwan adult metabolic fatty liver prevalence","value":"33.3","unit":"%","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"},{"claim":"Taiwan people with fatty liver","value":"~700","unit":"x10k people","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"},{"claim":"MASH patients with moderate-severe fibrosis at diagnosis","value":"40–52","unit":"%","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"},{"claim":"Liver cancers linked to fatty liver","value":"~20","unit":"%","as_of":"2026-06-09","source":"亞太新聞網 2026-06-09"}],"sections":["01｜GLP-1s clear the inflammation, not the scars","02｜The deal terms put the upside on cirrhosis","03｜Rezdiffra grew alongside the GLP-1s","04｜How the business changes","05｜What would prove this wrong","06｜Taiwan: seven million patients, and only the front-end drug","References"],"references":[{"title":"Liver Drug Saroglitazar Nearly Triples Placebo's MASH Resolution Rate","source":"Tech Times","date":"2026-11-08","url":"https://www.techtimes.com/articles/330261/20261108/liver-drug-saroglitazar-nearly-triples-placebos-mash-resolution-rate-zydus-trial-shows.htm"},{"title":"Survodutide Improves MASH Liver Endpoints Across Weight Loss Categories","source":"HCPLive","date":"2026-11-07","url":"https://www.hcplive.com/view/survodutide-improves-mash-liver-endpoints-across-weight-loss-categories"},{"title":"GLP-1s Lower MASH Activity but Not Fibrosis: Winston Dunn","source":"AJMC","date":"2026-11-07","url":"https://www.ajmc.com/view/glp-1s-lower-mash-activity-but-not-fibrosis-winston-dunn-md-faasld"},{"title":"Madrigal Announces New Real-World Data at AASLD 2026","source":"GlobeNewswire","date":"2026-11-05","url":"https://www.globenewswire.com/news-release/2026/11/05/3396655/0/en/madrigal-announces-new-real-world-data-at-aasld-2026-demonstrating-improvements-in-liver-stiffness-and-cardiometabolic-health-markers-with-rezdiffra.html"},{"title":"Madrigal Third Quarter 2026 Financial Results","source":"SEC","date":"2026-11-03","url":"https://www.sec.gov/Archives/edgar/data/0001157601/000162828026069093/exhibit991-93026earningspr.htm"},{"title":"GSK showcases progress in liver portfolio at AASLD 2026","source":"GSK","date":"2026-11-05","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-showcases-progress-in-liver-portfolio-at-aasld-2026/"},{"title":"Novo to present new liver data at AASLD 2026","source":"PR Newswire","date":"2026-10-28","url":"https://www.prnewswire.com/news-releases/novo-to-present-new-liver-data-across-wegovy-2-4-mg-and-investigational-efruxifermin-at-the-liver-meeting-aasld-2026--302922177.html"},{"title":"Novo Nordisk Financial Report Q3 2026","source":"SEC","date":"2026-11-04","url":"https://www.sec.gov/Archives/edgar/data/0000353278/000162828026069805/caq32026.htm"},{"title":"Novo Nordisk to acquire Akero Therapeutics","source":"Novo Nordisk","date":"2025-10-09","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916433"},{"title":"Roche becomes MASH player via $3.5B deal for 89bio","source":"Fierce Biotech","date":"2025-09-18","url":"https://www.fiercebiotech.com/biotech/roche-becomes-mash-player-35b-deal-89bio-and-its-phase-3-drug"},{"title":"FDA Approves Semaglutide (Wegovy) for Noncirrhotic MASH","source":"HCPLive","date":"2025-08-15","url":"https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash"},{"title":"Semaglutide Shows Lack of Improvement in Liver Fibrosis","source":"HCPLive","date":"2023-03-20","url":"https://www.hcplive.com/view/semaglutide-well-tolerated-shows-lack-improvement-liver-fibrosis"},{"title":"Intercept Complete Response Letter for Obeticholic Acid","source":"SEC","date":"2023-06-22","url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923073909/tm2319514d1_ex99-1.htm"},{"title":"Fatty liver affects one in three Taiwanese adults","source":"Asia Pacific News Network (yam","date":"2026-06-09","url":"https://n.yam.com/Article/20260609146222"},{"title":"2025 Cause of Death Statistics","source":"Ministry of Health and Welfare, Taiwan","date":"2026-06-22","url":"https://mohw.gov.tw/cp-16-86970-1.html"}],"images":[{"alt":"Fig. 1｜Resolution is easy, fibrosis is hard","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en/figure-01.png"},{"alt":"Fig. 2｜Four big pharmas bet on cirrhosis","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en/figure-02.png"},{"alt":"Fig. 3｜Two-drug era: GLP-1 for the front end","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en/figure-03.png"},{"alt":"Figure 4","url":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-13）。Weight-loss shots stop short of cirrhosis, so Novo bought a $4.7B fix。https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “At AASLD 2026, survodutide patients losing 15% or more saw 78.4% MASH resolution but 64.9% fibrosis improvement”?","a":"At AASLD 2026, survodutide patients losing 15% or more saw 78.4% MASH resolution but 64.9% fibrosis improvement."},{"q":"What are the key developments in “Novo's Akero CVR and Roche's 89bio CVR both depend on FGF21 success in cirrhosis”?","a":"Novo's Akero CVR and Roche's 89bio CVR both depend on FGF21 success in cirrhosis."},{"q":"What are the key developments in “Rezdiffra Q3 2026 sales reached $431.3 million, up 50%, with up to 53% of patients also on a GLP-1”?","a":"Rezdiffra Q3 2026 sales reached $431.3 million, up 50%, with up to 53% of patients also on a GLP-1."}]}